 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Martin McCarter and Eduardo Davila.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.777 |
|
|
|
-
Geng D, Chen J, Sanchez A, Davalos SA, Wilcox P, Gonzales-Rivera D, Couts K, Tobin R, Robinson W, Nielsen AJ, Guo J, McCarter M, Crump L, Tsujimoto K, Wilky BA, Davila E. Melanoma leverages innate immune IRAK-M signaling to limit metastasis through PTPN22-Induced signaling repression. Cancer Lett. 2026 Feb 28; 639:218172.
Score: 0.238
-
Nielsen AJ, Albert GK, Sanchez A, Chen J, Liu J, Davalos AS, Geng D, Bradeen X, Hintzsche JD, Robinson W, McCarter M, Amato C, Tobin R, Couts K, Wilky BA, Davila E. DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors. J Clin Invest. 2024 10 22; 134(24).
Score: 0.221
-
Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, Katsnelson E, Couts KL, Jordan KR, Gao D, Davila E, Medina TM, Lewis KD, Gonzalez R, McFarland RW, Robinson WA, McCarter MD. Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 04 03; 29(7):1209-1219.
Score: 0.198
-
MacBeth ML, Bagby SM, Borgers JSW, Turner JA, Anderson K, Whitty PA, Hartman SJ, Yacob B, Rebecca VW, Davila E, Pitts TM, Medina TM, Patel SP, McCarter MD, Robinson WA, Tobin RP, Couts KL. Decitabine reverses innate immune gene suppression in rare melanomas. Mol Cancer Ther. 2026 Jul 14.
Score: 0.062
-
MacBeth ML, Bagby SM, Borgers JSW, Turner JA, Anderson KC, Whitty PA, Hartman S, Yacob B, Rebecca VW, Davila E, Pitts TM, Medina TM, Patel SP, McCarter MD, Robinson WA, Tobin RP, Couts KL. Decitabine reverses innate immune gene suppression in rare melanomas. bioRxiv. 2025 Aug 28.
Score: 0.058
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|